Taking everything into account, WVE scores 4 out of 10 in our fundamental rating. WVE was compared to 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for WVE as it has an excellent financial health rating, but there are worries on the profitability. WVE is valued quite expensive, but it does show an excellent growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.62% | ||
| ROE | -92.42% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.49 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 2.5 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
13.84
-0.99 (-6.68%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 21.18 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 17.53 | ||
| P/tB | 17.53 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.62% | ||
| ROE | -92.42% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 23.08% | ||
| Cap/Sales | 0.74% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 2.5 | ||
| Altman-Z | 5.49 |
ChartMill assigns a fundamental rating of 4 / 10 to WVE.
ChartMill assigns a valuation rating of 0 / 10 to WAVE LIFE SCIENCES LTD (WVE). This can be considered as Overvalued.
WAVE LIFE SCIENCES LTD (WVE) has a profitability rating of 0 / 10.
The Earnings per Share (EPS) of WAVE LIFE SCIENCES LTD (WVE) is expected to decline by -52.05% in the next year.